ProCE Banner Activity

CheckMate 067: Nivolumab + Ipilimumab and Nivolumab Alone Superior to Ipilimumab Alone in Previously Untreated Advanced Melanoma

Slideset Download
Conference Coverage
Data from this large phase III trial suggest that the combination of nivolumab + ipilimumab offers better efficacy vs ipilimumab alone, but also better efficacy vs nivolumab alone, particularly for patients whose tumors are low in PD-L1 expression.

Released: June 02, 2015

Expiration: May 31, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation